{"id":"tumor-tissue","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["Severe liver dysfunction","Significant hepatopulmonary shunting","Pregnancy","Prior hepatic radiation","High bilirubin levels","Uncorrectable gastrointestinal flow","Child-Pugh C cirrhosis","Portal vein thrombosis","Renal insufficiency","Liver dysfunction","Hepatopulmonary shunting"],"specialPopulations":{"Pregnancy":"Renal tumors during pregnancy are rare and the treatment requires evaluation of both the patient and the fetus. Issues that need to be considered include the safety of imaging, the effect of treatment on the fetus and the mother, the timing of intervention, and prognosis. The general rules of kidney tumor management in non-pregnant patients and the guidelines for surgery in pregnancy could be referred to. Renal tumors found in pregnant patients require an individualized treatment regimen involving surgical timing, routes, techniques, and excision ranges, which should be decided based on the assessment of the oncologic risk and renal function, the general health and comorbidities, and more importantly, the experience of the surgical team. Although no consensus or guidelines for the management of renal tumors in pregnant patients has been proposed or verified, a timely diagnosis has prognostic benefits because the intervention would be much easier before the tumor progresses further and when the uterine is relatively small.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tumor-tissue","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:47:55.107652+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:01.374745+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:47:55.129217+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tumor-tissue","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:02.169864+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2074849/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:02.988182+00:00"}},"allNames":"tumor tissue","offLabel":[],"timeline":[],"_dailymed":null,"brandName":"Tumor Tissue","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Investigational","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The technical details of Tumor Tissue's mechanism are not publicly available, which is common for drugs in early development stages."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:29:01.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","launchDate":null,"annualCostUS":"$348,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tumor-tissue","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tumor-tissue","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:05.087116+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"PPAR γ","company":"N/A","advantage":"reprogramming tumor systems functions"},{"name":"mTOR","company":"N/A","advantage":"reprogramming tumor systems functions"},{"name":"pioglitazone","company":"N/A","advantage":"repurposed, regulatorily active drug combinations"},{"name":"metronomic chemotherapy","company":"N/A","advantage":"reprogramming tumor systems functions"},{"name":"anakoinosis","company":"N/A","advantage":"reprogramming tumor systems functions"},{"name":"biomodulation","company":"N/A","advantage":"reprogramming tumor systems functions"},{"name":"MEK","company":"N/A","advantage":"classic targeted therapies"},{"name":"immune checkpoints","company":"N/A","advantage":"classic targeted therapies"}],"genericName":"tumor-tissue","indications":{"approved":[{"name":"Anaplastic Large Cell Lymphoma","regulator":"FDA"},{"name":"Anaplastic Thyroid Carcinoma","regulator":"FDA"},{"name":"Basal Cell Carcinoma","regulator":"FDA"},{"name":"Blastoid Mantle Cell Lymphoma","regulator":"FDA"},{"name":"Breast Cancer","regulator":"FDA"},{"name":"Cervical Cancer","regulator":"FDA"},{"name":"Chordoma","regulator":"FDA"},{"name":"Chordoma, Chondroid","regulator":"FDA"},{"name":"Chordoma, Dedifferentiated","regulator":"FDA"},{"name":"Chordoma, Enchondroid","regulator":"FDA"},{"name":"Chordoma, Myxoid","regulator":"FDA"},{"name":"Chordoma, Not Otherwise Specified","regulator":"FDA"},{"name":"Chordoma, Papillary","regulator":"FDA"},{"name":"Chordoma, Squamous","regulator":"FDA"},{"name":"Chordoma, Squamous with Megakaryoblastic Differentiation","regulator":"FDA"},{"name":"Chordoma, Squamous with Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","regulator":"FDA"},{"name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","regulator":"FDA"}],"offLabel":[],"pipeline":["Cancer (various types)"]},"_drugWebsite":{"url":"https://www.tumortissue.com","content":"The domain tumortissue.com is for sale. To purchase, call Afternic.com at +1 781-373-6847 or 855-201-2286. Click here for more details.\nTUMORTISSUE.COM\nRelated Search Topics\nAvenio Tumor Tissue Cgp Kit V2\nTumor Tissue Array\nFrozen Tumor Tissue\nCalifornia Tumor Tissue Registry\nNecrotic Tumor Tissue\nH&e Staining Of Tumor Tissue\nCopyright © TUMORTISSUE.COM.  All rights reserved.\nPrivacy Policy"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00005902","phase":"","title":"Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2001-02-15","conditions":"Hemangioblastoma, Hippel Lindau Disease","enrollment":250},{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT02146170","phase":"","title":"Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-28","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer","enrollment":2000},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT03816345","phase":"PHASE1","title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Autoimmune Disease, Crohn Disease, Dermatomyositis","enrollment":300},{"nctId":"NCT06439836","phase":"PHASE1","title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-05","conditions":"Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":27},{"nctId":"NCT01660984","phase":"","title":"Natural History Study of Children and Adults With Medullary Thyroid Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-30","conditions":"Medullary Thyroid Cancer","enrollment":259},{"nctId":"NCT02372448","phase":"NA","title":"Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-01-23","conditions":"Lung Neoplasms","enrollment":206},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT07396584","phase":"PHASE1, PHASE2","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-04","conditions":"Solid Tumors, Adult","enrollment":186},{"nctId":"NCT07408375","phase":"NA","title":"Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-13","conditions":"Solid Tumor (Excluding CNS)","enrollment":560},{"nctId":"NCT06836869","phase":"NA","title":"Modified Tumor-free Techniques Operation to Cervical Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-20","conditions":"Cervical Cancer Stage IB2","enrollment":524},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT00001595","phase":"","title":"An Investigation of Pituitary Tumors and Related Hypothalmic Disorders","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1997-04-21","conditions":"Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma","enrollment":2000},{"nctId":"NCT07061964","phase":"PHASE2","title":"Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-25","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":111},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT07147231","phase":"PHASE1, PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461) in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":86},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT02594202","phase":"","title":"Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-21","conditions":"Prostate Cancer","enrollment":3000},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT06579469","phase":"","title":"Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-01-20","conditions":"B-ALL, Hematologic Malignancy, Solid Tumor","enrollment":100},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":27},{"nctId":"NCT07498933","phase":"","title":"FAP-targeted PET/NIR in Lung Malignant Tumors","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-06-03","conditions":"Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy","enrollment":200},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT07486128","phase":"","title":"Microplastics in Pancreas: Oncologic and Metabolic Impact","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-04-01","conditions":"Pancreatic Diseases, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT06308822","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT06501729","phase":"NA","title":"Kissing as a Protective Factor Against Acidic pH in Saliva","status":"COMPLETED","sponsor":"Universidad Catolica Santiago de Guayaquil","startDate":"2024-07-30","conditions":"Dental Caries, Tooth Demineralization, Teeth Erosion Limited to the Enamel","enrollment":45},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT05327010","phase":"PHASE2","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-14","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":88},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT06630338","phase":"","title":"Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-06-01","conditions":"Brain Tumor, Recurrent Brain Tumor, Brain Neoplasm","enrollment":30},{"nctId":"NCT02243592","phase":"","title":"Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-24","conditions":"Malignant Neoplasm","enrollment":170},{"nctId":"NCT06351371","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-03","conditions":"Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT02923778","phase":"PHASE2","title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-31","conditions":"Leiomyosarcoma, Liposarcoma, Sarcoma G2","enrollment":40},{"nctId":"NCT02865837","phase":"NA","title":"Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2015-09","conditions":"Cervical Cancer","enrollment":22},{"nctId":"NCT07284121","phase":"","title":"A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-17","conditions":"Lung Cancer, Hepatocellular Carcinoma","enrollment":700},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT05859334","phase":"PHASE2","title":"Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-04","conditions":"Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma","enrollment":30},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT05687136","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-07","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT06544187","phase":"","title":"Can Imaging be an Alternative to Exercise Testing as a Predictor of Surgical Fitness?","status":"RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2025-01-06","conditions":"Surgical Fitness, Imaging","enrollment":56},{"nctId":"NCT07062016","phase":"","title":"Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-01","conditions":"Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer","enrollment":100},{"nctId":"NCT04595747","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-03","conditions":"Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor","enrollment":48},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT04334941","phase":"PHASE2","title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":103},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT03824483","phase":"PHASE2","title":"Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-02-22","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)","enrollment":230},{"nctId":"NCT07424547","phase":"PHASE1","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2026-03-03","conditions":"Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer","enrollment":386},{"nctId":"NCT06599879","phase":"NA","title":"Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2025-10-21","conditions":"Brain Tumor, Pediatric","enrollment":130},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT07495098","phase":"PHASE1","title":"Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-07-01","conditions":"Lung Cancer Metastatic, Lung Cancer (NSCLC)","enrollment":12},{"nctId":"NCT00001975","phase":"","title":"Study of Skin Tumors in Tuberous Sclerosis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2000-01-26","conditions":"Tuberous Sclerosis","enrollment":400},{"nctId":"NCT07069699","phase":"PHASE1, PHASE2","title":"Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-13","conditions":"Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","enrollment":50},{"nctId":"NCT04955808","phase":"","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-07","conditions":"Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma","enrollment":2400},{"nctId":"NCT02978625","phase":"PHASE2","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-27","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma","enrollment":68},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT04314401","phase":"","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-11","conditions":"Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":1600},{"nctId":"NCT01087333","phase":"","title":"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03-02","conditions":"Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL)","enrollment":1263},{"nctId":"NCT04260256","phase":"PHASE2","title":"A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors","status":"TERMINATED","sponsor":"CellSight Technologies, Inc.","startDate":"2022-03-01","conditions":"Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit","enrollment":9},{"nctId":"NCT03386357","phase":"PHASE2","title":"Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2018-07-20","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":115},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT05588141","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-16","conditions":"Brain Tumor, Cancer","enrollment":96},{"nctId":"NCT05554341","phase":"PHASE2","title":"Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-14","conditions":"Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":40},{"nctId":"NCT00341276","phase":"","title":"Esophageal Cancer Genetics Studies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-07-06","conditions":"Esophageal Cancer, Gastric (Cardia, Body) Cancer","enrollment":7705},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04548752","phase":"PHASE2","title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-22","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":88},{"nctId":"NCT06287775","phase":"PHASE1, PHASE2","title":"Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-08","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":45},{"nctId":"NCT07488702","phase":"","title":"Intradurale Spinal Tumors: Management and Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria","startDate":"2022-01-01","conditions":"Spinal Cord Neoplasms, Spinal Neoplasms","enrollment":50},{"nctId":"NCT05630794","phase":"PHASE1","title":"Testing for Safety and Colorectal Cancer Preventive Effects of ONC201","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-06","conditions":"Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis","enrollment":36},{"nctId":"NCT06223542","phase":"PHASE1","title":"Studying TAK-243 in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-24","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma","enrollment":95},{"nctId":"NCT05554380","phase":"PHASE2","title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-22","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT05145647","phase":"NA","title":"To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-30","conditions":"Esophageal Cancer","enrollment":18},{"nctId":"NCT02390752","phase":"PHASE1","title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-29","conditions":"Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute","enrollment":54},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT07436728","phase":"PHASE1, PHASE2","title":"A Study of TAK-505 in Adults With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Malignant Solid Tumors","enrollment":151},{"nctId":"NCT04541654","phase":"","title":"Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-09-15","conditions":"Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome","enrollment":1500},{"nctId":"NCT03030378","phase":"PHASE1","title":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-30","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT07489976","phase":"PHASE2","title":"IIT2025-03-YANG-LIFT-HCC","status":"RECRUITING","sponsor":"Ju Dong Yang","startDate":"2026-04-01","conditions":"Hepato Cellular Carcinoma","enrollment":41},{"nctId":"NCT05691517","phase":"PHASE1","title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-12","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT04340843","phase":"PHASE2","title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-08","conditions":"Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma","enrollment":19},{"nctId":"NCT05687110","phase":"PHASE1","title":"Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-06","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":43},{"nctId":"NCT05554328","phase":"PHASE2","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-25","conditions":"Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":165},{"nctId":"NCT02015117","phase":"PHASE1","title":"Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-28","conditions":"Metastatic Malignant Neoplasm in the Brain","enrollment":10},{"nctId":"NCT00477958","phase":"NA","title":"Assessment Tool for Older Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-12-19","conditions":"Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1062}],"_emaApprovals":[{"date":"","name":"Tumor Tissue","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2074849","moleculeType":"Unknown","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2074849"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":34687,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"348000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:05.087116+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}